Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by GÓMEZ-VAQUERO, C.
Right arrow Articles by ROIG-ESCOFET, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GÓMEZ-VAQUERO, C.
Right arrow Articles by ROIG-ESCOFET, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 British Society for Rheumatology

other

TERMINATION OF DISEASE-MODIFYING DRUGS IN PSORIATIC ARTHRITIS: STUDY OF 109 COURSES OF TREATMENT

C. GÓMEZ-VAQUERO, J. RODRÍGUEZ-MORENO, S. ROS, R. MARCOS*, J. FTTER and D. ROIG-ESCOFET

*Preventive Medicine Services, Ciutat Sanitària i Universitària de Belhitge Barcelona, Spain
Rheumatology Department, Ciutat Sanitària i Universitària de Belhitge Barcelona, Spain

Correspondence to: Correspondence to: C. Gómez-Vaquero, Ciutat Sanitària i Universitària de Bellvitge, Rheumatology Service (PI 10–2), Feixa Liarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.

Our aim is to study the termination of disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA) and the causes of withdrawal. We have reviewed the prospective protocols of patients with PsA and collected the data on treatments and causes of withdrawal. Fifty-four out of 96 patients (48 male and 48 female) have undergone one or more courses of DMARD (n = 109). The life-table analysis shows a survival rate of 6 months for gold sodium thiomalate (GOLD) and sulphasalazine (SSZ), and 16 months for methotrexate (MTX). The Mantel-Haenszel test finds statistical differences between GOLD and MTX. There are no differences between MTX and SSZ or between GOLD and SSZ. The absence of differences for MTX and SSZ could be explained by the heterogeneity of both groups. The most common cause of withdrawal for GOLD and SSZ are adverse effects.

KEY WORDS: Psoriatic arthritis, Disease-modifying anti-rheumatic drugs, Life-table analysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
P Nash and D O Clegg
Psoriatic arthritis therapy: NSAIDs and traditional DMARDs
Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii74 - ii77.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.